ADVENZYMES Advanced Enzyme Technologies Q3 FY25 results (Oct–Dec 2024) and concall
Advanced Enzyme Technologies reported a mixed Q3 FY25, showcasing strong sequential and year-on-year growth in revenue and EBITDA, driven by robust performance in Bioprocess and Specialized Manufacturing segments. However, year-to-date revenue growth remained modest, and the company anticipates flat sales in India for FY25. Strategic focus includes nutraceuticals, R&D, and potential acquisitions, while navigating global economic uncertainties and competitive pressures.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
| Line item | Q2 FY25 | Q3 FY25 |
|---|---|---|
| Revenue | 77 | 101 |
| EBITDA | 14 | 22 |
| Net profit | 9 | 15 |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
